Fast biotech: Gilead hands $200M to computational wiz Nimbus as it speeds into PhII NASH trial
When Nimbus Therapeutics CEO Don Nicholson structured his $1.2 billion licensing deal with Gilead $GILD earlier this year, he built it with the Big Biotech’s rep for focus, science and clinical speed in mind.
It paid off. Fast.
Today, Cambridge, MA-based Nimbus is revealing that it grabbed a $200 million milestone from Gilead for its early-stage NASH drug, just 6 months after nabbing a $400 million upfront payment. The payout now gives them $600 million this year, half of that $1.2 billion deal total that Gilead signed off on.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.